Sundaram Finance Q1 FY27 Results Analysis: PAT Jumps 21.7%, Asset Quality Weakens (SUNDARMFIN)

CompoundingAI Research Updated August 03, 2026 2 min read
Positive

Sundaram Finance Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 2,075.99 Cr (+10.24% YoY) and PAT growth of +21.67% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 03, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 2,075.99 Cr (+10.24% YoY)
PAT (Q1)Rs. 521.61 Cr (+21.67% YoY)
EPS (Q1)Rs. 46.95 (+21.66% YoY)
Market capRs. 53,635.80 Cr
CMPRs. 4,823.45

Quarter Snapshot

Sundaram Finance delivered strong YoY growth in PAT (21.7% standalone) and NII (17.2%), aided by declining credit costs and operating leverage. However, asset quality weakened sequentially (Gross Stage 3 rose to 1.71%), employee costs grew faster than revenue, and capital adequacy continued to erode. The quarter highlights a mix of positive momentum and emerging risks that warrant monitoring.

Key Investment Insights

Key Positives

  • Standalone PAT grew 21.67% YoY to Rs.521.61 Cr; consolidated PAT grew 33.88% YoY to Rs.636.19 Cr.
  • Net Interest Income grew 17.20% YoY, outpacing revenue growth of 10.24%.
  • Impairment/provisions declined 30.85% YoY to Rs.108.84 Cr, reflecting lower credit costs.
  • Asset Financing segment margin expanded 466 bps YoY to 28.63%.
  • Cost of funds well-managed; finance cost grew 8.75% YoY vs interest income growth of 12.39%.

Risk Factors

  • Gross Stage 3 increased QoQ from 1.44% to 1.71%, breaking the H2FY26 improvement trend.
  • Employee benefit expenses grew 21.07% YoY, significantly faster than revenue growth, partly due to ESOPs.
  • Capital Adequacy Ratio declined from 20.01% to 18.49% over four quarters, continuing erosion.
  • Others segment (non-lending) revenue growth slowed and margin compressed from 38.65% to 35.08%.
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.

Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings

Login Now